Related Experiment Video
Updated: May 14, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Cox-2 gene variants in migraine
Selcuk Dasdemir1, Yilmaz Cetinkaya, Mehmet Gencer
1Department of Molecular Medicine, Institute of Experimental Medicine Research, Istanbul University, Istanbul, Turkey.
Gene
|January 30, 2013
Summary
This study found that the COX-2-765 G+ genotype is associated with an increased risk of developing migraine. Conversely, the COX-2-765 C+ genotype appears to decrease migraine risk, suggesting a role for COX-2 gene variants in migraine pathogenesis.
Area of Science:
- Genetics
- Neurology
- Pharmacology
Background:
- Migraine is a complex neurological disorder lacking clear diagnostic markers.
- Nonsteroidal anti-inflammatory drugs, including those targeting COX-2, are used to manage migraine pain.
- Understanding the genetic basis of migraine is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the association between cyclooxygenase-2 (COX-2) gene polymorphisms (COX-2-765G→C and COX-2-1195A→G) and the risk of migraine.
- To explore the potential role of COX-2 genetic variations in migraine pathogenesis.
Main Methods:
- Prospective study involving 144 migraine patients and 123 non-case subjects.
- Genotyping of COX-2 gene polymorphisms using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP).
Main Results:
- A significant association was found between COX-2 gene variants and an increased risk of migraine.
- The COX-2-765 G+ genotype was more frequent in migraine patients, suggesting an increased risk.
- The COX-2-765 C+ genotype was more frequent in controls, indicating a potentially decreased risk.
- The COX-2-1195 AG genotype showed a statistically significant difference between patients and controls.
Conclusions:
- The COX-2-765 G+ genotype may facilitate the development of migraine.
- These findings highlight the potential role of specific COX-2 gene polymorphisms in migraine susceptibility.
- Further research into COX-2 genetic variations could inform migraine diagnosis and treatment strategies.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:33Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...